Nutra Pharma Statistics
Total Valuation
Nutra Pharma has a market cap or net worth of 709,974. The enterprise value is 9.27 million.
| Market Cap | 709,974 |
| Enterprise Value | 9.27M |
Important Dates
The next estimated earnings date is Friday, November 21, 2025.
| Earnings Date | Nov 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutra Pharma has 7.10 billion shares outstanding.
| Current Share Class | 7.10B |
| Shares Outstanding | 7.10B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +108.83% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 0.25.
| PE Ratio | 0.25 |
| Forward PE | n/a |
| PS Ratio | 1.62 |
| PB Ratio | -0.06 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 1.13 |
| EV / Sales | 21.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.30 |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -10.42 |
| Interest Coverage | -2.41 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -155.33% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 15.97% |
| Revenue Per Employee | 109,569 |
| Profits Per Employee | 2.04M |
| Employee Count | 6 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 6.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 33.93 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 43.43 |
| Average Volume (20 Days) | 714,934 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Nutra Pharma had revenue of 438,274 and earned 8.18 million in profits. Earnings per share was 0.00.
| Revenue | 438,274 |
| Gross Profit | 249,022 |
| Operating Income | -1.91M |
| Pretax Income | 8.18M |
| Net Income | 8.18M |
| EBITDA | -1.88M |
| EBIT | -1.91M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | 8.55M |
| Net Cash | -8.55M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -12.38M |
| Book Value Per Share | -0.00 |
| Working Capital | -12.37M |
Cash Flow
In the last 12 months, operating cash flow was -762,432 and capital expenditures -57,993, giving a free cash flow of -820,425.
| Operating Cash Flow | -762,432 |
| Capital Expenditures | -57,993 |
| Free Cash Flow | -820,425 |
| FCF Per Share | -0.00 |
Margins
Gross margin is 56.82%, with operating and profit margins of -435.21% and 1,865.70%.
| Gross Margin | 56.82% |
| Operating Margin | -435.21% |
| Pretax Margin | 1,865.70% |
| Profit Margin | 1,865.70% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nutra Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -164.04% |
| Shareholder Yield | n/a |
| Earnings Yield | 1,151.71% |
| FCF Yield | -115.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 18, 2015. It was a reverse split with a ratio of 0.025.
| Last Split Date | May 18, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
Nutra Pharma has an Altman Z-Score of -163.41 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -163.41 |
| Piotroski F-Score | 3 |